CoreAge Rx
Compounded semaglutide and tirzepatide
The useful question
Examine the offer ↗Which preparation, pharmacy and purchase term does the proposed plan specify?
An explainer for the curious patient
Two pathways.
Better questions.
What does “dual” actually mean? Which study supports that claim? And what changes when the product changes?
Start with the mechanism ↗A concept, not a score
GIPreceptor
+GLP-1receptor
TirzepatideOne medicine · two receptor targets
Receptor activity explains a mechanism.
Clinical studies investigate outcomes.
Before asking how much better,
ask what was actually compared.
The explainer series
View the complete series ↗Follow the question.
Mechanism01
What “dual incretin” means—and what it leaves unanswered
Two receptor targets describe how a medicine acts. They do not give a patient a treatment ranking.
Read the explainer ↗Study reading02
How to read a head-to-head tirzepatide study
A result becomes more useful when the population, comparator and limits travel with it.
Read the explainer ↗Product identity03
Ingredient, brand and preparation: three labels to keep separate
A familiar ingredient name cannot do all the work of identifying the medicine in an offer.
Read the explainer ↗The medicine is one part.
The care is another.
SuperHealthy Rx
Bundled compounded-medication promotion
The useful question
Examine the offer ↗Does the dated promotional page match the product and terms at checkout?
Likeness Rx
Compounded GLP-1 plans with several payment terms
The useful question
Examine the offer ↗What obligation sits behind the lowest displayed monthly equivalent?
Mechanism ≠ personal outcome.
Ingredient ≠ product approval.
Placement ≠ clinical evidence.